MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 81 filers reported holding MARINUS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.67 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $25,357,500 | -25.9% | 3,150,000 | 0.0% | 0.40% | -14.7% |
| Q2 2023 | $34,209,000 | +57.4% | 3,150,000 | 0.0% | 0.46% | +44.1% |
| Q1 2023 | $21,735,000 | +73.4% | 3,150,000 | 0.0% | 0.32% | +72.2% |
| Q4 2022 | $12,537,000 | -40.2% | 3,150,000 | 0.0% | 0.19% | -51.7% |
| Q3 2022 | $20,948,000 | +37.4% | 3,150,000 | 0.0% | 0.39% | +28.6% |
| Q2 2022 | $15,246,000 | -48.2% | 3,150,000 | 0.0% | 0.30% | -44.1% |
| Q1 2022 | $29,453,000 | -23.4% | 3,150,000 | -2.6% | 0.54% | -17.7% |
| Q4 2021 | $38,432,000 | +4.4% | 3,235,000 | 0.0% | 0.65% | +13.1% |
| Q3 2021 | $36,814,000 | -36.6% | 3,235,000 | 0.0% | 0.58% | -42.8% |
| Q2 2021 | $58,036,000 | +15.9% | 3,235,000 | 0.0% | 1.01% | +16.8% |
| Q1 2021 | $50,078,000 | +27.0% | 3,235,000 | +0.1% | 0.86% | +27.4% |
| Q4 2020 | $39,432,000 | – | 3,232,142 | – | 0.68% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
| Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
| Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
| Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
| Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
| Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
| Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |